CD274 and neoplasm: Ibrutinib can inhibit regulatory T-cells (Tregs), promote the activation of cytotoxic T-cells (CTLs) and enhance the secretion of inflammatory cytokines (Gopal et al., 2018), expected to provide a more favorable tumor microenvironment (TME) for PD-1/PD-L1 mAb.